PureTech Health plc (LON:PRTC - Get Free Report)'s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 134.80 ($1.66) and last traded at GBX 136.40 ($1.68), with a volume of 325557 shares trading hands. The stock had previously closed at GBX 138 ($1.70).
Analyst Ratings Changes
Separately, Jefferies Financial Group reissued a "buy" rating and set a GBX 455 ($5.60) target price on shares of PureTech Health in a research report on Monday, December 16th.
Get Our Latest Stock Report on PureTech Health
PureTech Health Price Performance
The stock has a market cap of £326.57 million, a P/E ratio of -593.04 and a beta of 1.02. The business has a 50 day simple moving average of GBX 157.66 and a 200-day simple moving average of GBX 159.51. The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
